Needham & Company LLC Cuts Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00

Autolus Therapeutics (NASDAQ:AUTL) had its price target trimmed by Needham & Company LLC from $11.00 to $10.00 in a report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also issued reports on the company. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research report on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.33.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.42 on Monday. The company has a 50-day moving average of $1.56 and a two-hundred day moving average of $1.75. The stock has a market cap of $377.92 million, a price-to-earnings ratio of -1.71 and a beta of 2.01. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.07). Autolus Therapeutics had a negative net margin of 439.69% and a negative return on equity of 63.76%. The firm had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Hennion & Walsh Asset Management Inc. raised its position in Autolus Therapeutics by 7.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 453,828 shares of the company’s stock valued at $903,000 after acquiring an additional 33,247 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Autolus Therapeutics by 64.9% during the 4th quarter. SG Americas Securities LLC now owns 66,678 shares of the company’s stock worth $133,000 after purchasing an additional 26,241 shares during the last quarter. Tudor Investment Corp ET AL raised its holdings in shares of Autolus Therapeutics by 93.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 206,653 shares of the company’s stock valued at $337,000 after purchasing an additional 100,000 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics during the 3rd quarter valued at $46,000. Finally, Armistice Capital LLC lifted its stake in shares of Autolus Therapeutics by 30.0% in the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after purchasing an additional 3,600,000 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.